IP Library › Granted Patent US 11,485,770
Granted Patent B2
US 11,485,770 · App. 17/575,425 · Granted Nov 1, 2022

Anti-VEGF protein compositions and methods for producing the same

Inventors: Shunhai Wang (Scarsdale, NY); Ning Li (New Canaan, CT); Hunter Chen (New York, NY); Amardeep Singh Bhupender Bhalla (Montvale, NJ)
Assignee: Regeneran Pharmaceuticals, Inc.
C07K14/71A61K38/1866C07K1/113C07K1/16C07K1/18C07K1/22C07K1/36C07K16/22C07K16/283C12N5/0018C12N5/0031C12N15/66C12P21/02C12P21/06G01N30/80C07K2317/622C07K2319/30C07K2319/33C12N2800/10G01N2030/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,485,770
App. No.
17/575,425
Granted
Nov 1, 2022
Kind
B2
Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Claims (14)

1. A culture media composition comprising chemically defined media (CDM) and oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and wherein said one or more amino acid residues is histidine and/or tryptophan.

2. A culture media composition of claim 1 , wherein said oxo-aflibercept is enzymatically digested resulting in one or more oligopeptides, and wherein said one or more oligopeptides selected from the group consisting of: SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 28, SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32 and combinations thereof.

3. A culture media composition of claim 1 further comprising SEQ ID NO. 17.

4. A culture media composition of claim 1 further comprising SEQ ID NO. 18.

5. A culture media composition of claim 1 further comprising SEQ ID NO. 19.

6. A culture media composition of claim 1 further comprising SEQ ID NO. 20.

7. A culture media composition of claim 1 further comprising SEQ ID NO. 21.

8. A culture media composition of claim 1 further comprising SEQ ID NO. 22.

9. A culture media composition of claim 1 further comprising SEQ ID NO. 23.

10. A culture media composition of claim 1 further comprising SEQ ID NO. 28.

11. A culture media composition of claim 1 further comprising SEQ ID NO. 29.

12. A culture media composition of claim 1 further comprising SEQ ID NO. 30.

13. A culture media composition of claim 1 further comprising SEQ ID NO. 31.

14. A culture media composition of claim 1 further comprising SEQ ID NO. 32.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2022
From: WANG, SHUNHAI; LI, NING; CHEN, HUNTER; BHUPENDER BHALLA, AMARDEEP SINGH
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 060537/0660 →
Continuity (5)
Division 17460578 · Aug 30, 2021
Continuation 16996293 · Aug 18, 2020
Provisional Application 63065012 · Aug 13, 2020
Provisional Application 62944635 · Dec 6, 2019
Related Publication 20220227835A1 · Jul 21, 2022
Cited By (1)
US 12,319,728